MetaCap

BeyondSpring (BYSI) vs Citius Pharmaceuticals (CTXR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Pharmaceuticals (CTXR) has outperformed BeyondSpring (BYSI) over the past year, losing 55.4% versus a loss of 82.8%. Over five years, BYSI leads with a -97.7% price change compared with -98.8% for CTXR. Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $13.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BYSI-82.77%CTXR-55.39%
+32%-28%-88%
Nov 21, 20251 yearNov 20, 2026
BYSI-97.51%CTXR-98.81%
+16%-44%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BYSI versus CTXR key metrics
MetricBYSICTXR
Share price$0.33$0.5085
Market cap$13.66M$13.96M
1-day change-24.49%+2.27%
YTD return-79.75%-34.56%
1-year return-82.77%-55.39%
5-year return-97.70%-98.79%
EPS (TTM)$-0.20$-1.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-1.01M$-39.74M
52-week high$2.44$1.54
52-week low$0.299$0.37
Distance from 52-week high-86.48%-66.98%
Analyst consensus—none
Avg. price target upside—+686.63%
Average volume261.79K275.44K
Shares outstanding41.41M27.45M
Employees4423
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTXR has outperformed BYSI by 27.4 percentage points over the past year.

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

BYSI vs CTXR FAQ

Which is bigger, BeyondSpring or Citius Pharmaceuticals?

Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $13.66M for BeyondSpring (BYSI).

Which stock has performed better over the past year, BYSI or CTXR?

CTXR returned -55.39% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.

Are BeyondSpring and Citius Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons